By Chris Wack
Minerva Neurosciences, Inc. shares were up 25%, to $3.50, after the company said that the U.S. Food and Drug Administration filed its New Drug Application for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
The company said the decision to file the NDA follows its request for formal dispute…
Read the full article here
